X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14570) 14570
Newsletter (100) 100
Magazine Article (71) 71
Newspaper Article (48) 48
Book Chapter (32) 32
Dissertation (19) 19
Web Resource (7) 7
Book Review (6) 6
Publication (4) 4
Conference Proceeding (3) 3
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11024) 11024
metformin (9782) 9782
hypoglycemic agents - therapeutic use (6906) 6906
metformin - therapeutic use (6867) 6867
female (6625) 6625
diabetes mellitus, type 2 - drug therapy (5584) 5584
male (5503) 5503
diabetes (4139) 4139
middle aged (4095) 4095
endocrinology & metabolism (3842) 3842
type 2 diabetes (3757) 3757
adult (3138) 3138
aged (2926) 2926
insulin (2803) 2803
glucose (2372) 2372
animals (2281) 2281
diabetes mellitus (2220) 2220
pharmacology & pharmacy (2082) 2082
insulin resistance (2015) 2015
treatment outcome (2008) 2008
diabetes mellitus, type 2 - blood (1886) 1886
drug therapy, combination (1841) 1841
hypoglycemic agents - adverse effects (1841) 1841
metformin - pharmacology (1745) 1745
care and treatment (1664) 1664
risk factors (1657) 1657
hypoglycemic agents - administration & dosage (1645) 1645
research (1565) 1565
glycemic control (1526) 1526
drug therapy (1516) 1516
diabetes therapy (1515) 1515
blood glucose - metabolism (1507) 1507
therapy (1479) 1479
risk (1455) 1455
metformin - administration & dosage (1428) 1428
mellitus (1414) 1414
analysis (1406) 1406
double-blind (1386) 1386
hypoglycemic agents (1386) 1386
hypoglycemic agents - pharmacology (1359) 1359
metformin - adverse effects (1324) 1324
medicine, general & internal (1317) 1317
insulin-resistance (1279) 1279
obesity (1259) 1259
insulin - therapeutic use (1236) 1236
health aspects (1175) 1175
cancer (1154) 1154
diabetes mellitus, type 2 - complications (1146) 1146
metabolism (1128) 1128
blood glucose - drug effects (1064) 1064
mortality (1033) 1033
internal medicine (1026) 1026
glycated hemoglobin a - metabolism (1008) 1008
hyperglycemia (996) 996
sulfonylurea compounds - therapeutic use (996) 996
dosage and administration (995) 995
thiazolidinediones - therapeutic use (982) 982
oncology (965) 965
clinical trials (963) 963
double-blind method (961) 961
body mass index (959) 959
efficacy (951) 951
mice (930) 930
adolescent (911) 911
medicine & public health (901) 901
endocrine system diseases (878) 878
polycystic ovary syndrome - drug therapy (878) 878
type 2 diabetes mellitus (835) 835
safety (833) 833
dextrose (822) 822
activated protein-kinase (803) 803
studies (803) 803
pregnancy (782) 782
kinases (768) 768
rats (768) 768
retrospective studies (759) 759
nutritional and metabolic diseases (753) 753
patients (739) 739
women (739) 739
diabetes mellitus, type 2 - metabolism (733) 733
management (724) 724
abridged index medicus (717) 717
glycated hemoglobin a - analysis (716) 716
young adult (716) 716
hypoglycemia (701) 701
diabetes mellitus - drug therapy (691) 691
medicine, research & experimental (686) 686
medicine (676) 676
aged, 80 and over (671) 671
insulin - blood (667) 667
drugs (662) 662
obstetrics & gynecology (660) 660
thiazolidinediones (660) 660
dipeptidyl-peptidase iv inhibitors - therapeutic use (653) 653
blood glucose - analysis (650) 650
sulfonylurea (641) 641
proteins (639) 639
time factors (636) 636
body weight (635) 635
prevention (627) 627
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14150) 14150
French (176) 176
German (172) 172
Spanish (104) 104
Chinese (55) 55
Japanese (51) 51
Russian (49) 49
Italian (46) 46
Polish (24) 24
Dutch (18) 18
Czech (16) 16
Hungarian (16) 16
Portuguese (16) 16
Swedish (9) 9
Danish (8) 8
Bulgarian (7) 7
Finnish (4) 4
Korean (3) 3
Norwegian (3) 3
Turkish (3) 3
Romanian (2) 2
Slovak (2) 2
Ukrainian (2) 2
Indonesian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
European heart journal, ISSN 1522-9645, 2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Diabetes and Metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2015, Volume 2017, Issue 5, p. CD010334
Background Hirsutism occurs in 5% to 10% of women of reproductive age when there is excessive terminal hair growth in androgen‐sensitive areas (male pattern).... 
Disorders of hair & nails | electrolysis | Desogestrel | Finasteride | Androgen Antagonists | bleaching | Hypoglycemic Agents | Spironolactone | Cyproterone Acetate | Contraceptive Agents, Female | hormonal therapy ie anti‐androgens such as spironolactone, cyproterone acetate (liaison with Cochrane Menstrual Disorders Group) | Body Mass Index | 1. Non‐medical treatments | Hirsutism | H. DISORDERS OF SKIN APPENDAGES (HAIR, NAILS, SWEAT GLANDS) | 2. Medical treatments | Ethinyl Estradiol | Skin disorders | Randomized Controlled Trials as Topic | Flutamide | H10 Excessive hair growth (hirsutism) | Quality of Life | Metformin | Medicine General & Introductory Medical Sciences | Drug Combinations | 5‐alpha Reductase Inhibitors | Eflornithine | POLYCYSTIC-OVARY-SYNDROME | MEDICINE, GENERAL & INTERNAL | ORAL-CONTRACEPTIVE PILLS | ESTRADIOL-CYPROTERONE ACETATE | LOW-DOSE PIOGLITAZONE | QUALITY-OF-LIFE | SPIRONOLACTONE PLUS FINASTERIDE | RANDOMIZED CONTROLLED-TRIAL | LONG-TERM TREATMENT | HORMONE-BINDING GLOBULIN | CARDIOVASCULAR RISK-FACTORS | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Contraceptive Agents, Female - therapeutic use | Humans | Desogestrel - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Eflornithine - therapeutic use | Hirsutism - drug therapy | Cyproterone Acetate - therapeutic use | Androgen Antagonists - therapeutic use | Adult | Female | Finasteride - therapeutic use | Flutamide - therapeutic use | Spironolactone - therapeutic use | Ethinyl Estradiol - therapeutic use
Journal Article
Diabetes care, ISSN 0149-5992, 2009, Volume 32, Issue 5, pp. 762 - 768
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with... 
NON-INFERIORITY | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | BASAL INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | TWICE-DAILY EXENATIDE | Metformin - therapeutic use | C-Peptide - blood | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Exenatide | Female | Insulin - analogs & derivatives | Insulin Secretion | Body Mass Index | Hypoglycemic Agents - therapeutic use | Insulin-Secreting Cells - physiology | Insulin, Long-Acting | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Insulin Glargine | Arginine - pharmacology | Venoms - therapeutic use | Kinetics | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Peptides - therapeutic use | Index Medicus | Original Research | Hemoglobin A | Insulin/analogs & derivatives/secretion/therapeutic use | Blood Glucose/metabolism | Type 2/blood/drug therapy/physiopathology | MEDICIN OCH HÄLSOVETENSKAP | Diabetes Mellitus | Insulin-Secreting Cells/drug effects/physiology | Venoms/therapeutic use | Metformin/therapeutic use | Glycosylated/metabolism | Peptides/therapeutic use | Arginine/pharmacology | Hypoglycemic Agents/therapeutic use | C-Peptide/blood | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal Article